A revision of the nearly 8-year-old World Health Organization classification of the lymphoid
neoplasms and the accompanying monograph is being published. It reflects a consensus …

Diffuse Large B-Cell Lymphoma DLBCL, an aggressive cancer, accounts for about 30% of
all lymphomas. Empirical combination chemotherapy cures about 65% of patients initially …

Mucosa-associated lymphoid tissue–derived lymphoma (MALT lymphoma) is usually a very
indolent lymphoma, described as localized at diagnosis and remaining localized for a …

Background The standard treatment for patients with diffuse large-B-cell lymphoma is
cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Rituximab, a chimeric …

Background Patients with diffuse large B-cell lymphoma that is refractory to primary and
second-line therapies or that has relapsed after stem-cell transplantation have a poor …

Given that the FcγRIIIa receptor 158V allotype displays a higher affinity for human
immunoglobulin G1 and increased antibody-dependent cellular cytotoxicity, the aim of this …

Since the publication of the Revised European-American Classification of Lymphoid
Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have …

Background Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only 60 …

Background Phosphatidylinositol-3-kinase delta (PI3Kδ) mediates B-cell receptor signaling
and microenvironmental support signals that promote the growth and survival of malignant B …

Background Patients with follicular lymphoma can have long survival times, but disease
progression typically occurs 3–5 years after initial treatment. We assessed the potential …